Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Prescription Drug User Fee Amendments

Prescription Drug User Fee Amendments Home
          For Industry
          FDA User Fee Programs
          Prescription Drug User Fee Amendments
          Update on In-Person Face-to-Face Formal Meetings with FDAPrescription Drug User Fee Amendments Update on In-Person Face-to-Face Formal Meetings with FDA
  
  	
    Share
    Post
    Linkedin

    Email
    PrintThe PDUFA VII and BsUFA III commitment letters provide an update to the definition of face-to-face formal meetings with industry. This update clarifies that a face-to-face meeting “includes in-person meetings and virtual meetings on IT platforms that allow for both audio and visual communication.”1 In other words, a face-to-face (FTF) meeting between FDA and industry is defined as either in-person or virtual with cameras on. While OMUFA does not have this formal definition, OMUFA meetings may also be conducted in-person or using the virtual meeting format allowing for both audio and visual communication.

In 2023, CDER and CBER staff transitioned to a hybrid workplace, with staff returning to work at the White Oak campus (on-site) for a portion of their time. This transition enabled in-person FTF formal meetings between FDA and industry to be restarted. To avoid overcrowding in the conference rooms, all in-person FTF formal meetings will have a hybrid component (virtual attendees in addition to in-person attendees). FDA’s focus is on having only core participants with a primary speaking role in-person while others join virtually. FDA encourages industry to follow this same pattern. To support hybrid meetings, FDA White Oak conference rooms were upgraded, in phases, over the course of 2023 with new technology (e.g., noise-cancelling, boom-forming microphones, face/conversation tracking video cameras). Completed upgrades enable FDA to fully return to in-person meetings.

**Beginning January 22, 2024, CDER and CBER will expand in-person FTF industry meetings (with a hybrid component) to include all PDUFA, BsUFA, and OMUFA meeting types.** If an in-person meeting is being requested, the sponsor should specify this in their request.  A final determination on the format will be made by the review division and communicated to the sponsor should the format be different than requested.  Existing meeting requests for the newly eligible meeting types received before January 22, 2024, or meetings already scheduled regardless of the scheduled meeting date, will not be converted to the in-person format, to permit fair implementation of the transition.

If there are general questions for CDER meetings, please reach out to ONDExecOps@fda.hhs.gov. Questions for CBER meetings should be directed to industry.biologics@fda.hhs.gov.

1See footnote 9 in PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2023 Through 2027, and footnote 2 in Biosimilar Biological Product Reauthorization Performance Goals and Procedures Fiscal Years 2023 Through 2027.

                                                                                  Content current as of:
      12/18/2023
              
              
Regulated Product(s)
		 DrugsPrescription Drug User Fee Amendments
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop